Long-term results of paclitaxel in FIGO stage III ovarian carcinoma.


:The combination of platinum and paclitaxel is the standard treatment of advanced ovarian carcinoma; however, recent studies have questioned the actual role of the combination as compared to either of the two agents alone. We report an open-label, two-center, phase II study of upfront paclitaxel for patients with histological diagnosis of stage III ovarian carcinoma. Treatment consisted of paclitaxel at 175 mg/m2 administered in a 3-h infusion every 21 days. Response was evaluated after the third course by either laparoscopy or exploratory laparotomy. Patients with stable or progressive disease discontinued treatment, whereas responding patients continued treatment until a maximum of six courses. Response, toxicity, time to progression (TTP) and survival were evaluated. From November 1993 to December 1995, 30 patients were accrued. All patients underwent primary cytoreduction; 17 (57%) and 13 (43%) patients had residual tumors <2 and >2 cm, respectively. Of 27 patients evaluable, objective responses were seen in 18 (66.4%) (95% CI 49.5-83.2)--12 complete (45%) and six partial (22%). Four patients had stable disease (15%) and five (18%) patients progressed. A total of 149 courses were administered to 30 patients, median 4 (range 1-6). Grade 3/4 neutropenia was seen in 13% of courses, peripheral neuropathy, myalgia and arthralgia were frequent, but transitory and relieved with analgesics. At a median follow-up time of 44.5 months (0-99) the TTP and median survival were 16.6 and 43.1 months, respectively. We conclude that single-agent paclitaxel is an effective and well-tolerated first-line treatment for advanced ovarian carcinoma.


Anticancer Drugs


Anti-cancer drugs


Gallardo-Rincón D,Pérez-Landeros L,Oñate-Ocaña LF,Mohar A,Calderillo G,de la Garza J,Cabrera P,Sánchez B,Dueñas-Gonzalez A




Has Abstract


2003-06-01 00:00:00












  • Selective delivery of etoposide to intraperitoneal tissues using a new dosage format: etoposide microcrystals suspended in oil.

    abstract::Rats received an intraperitoneal bolus injection of etoposide at 5 mg/kg of body weight in the form of an etoposide microcrystal suspension in oil (ETOP-OIL) or an aqueous etoposide solution. The tissue distribution was subsequently analyzed using high performance liquid chromatography. ETOP-OIL delivered significantl...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Hagiwara A,Takahashi T,Lee M,Sakakura C,Shoubayashi S,Tashima S,Yamamoto A,Muranishi S

    更新日期:1993-02-01 00:00:00

  • A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.

    abstract::The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients. The following treatment was given: on day 1 of a 21-day cycle, oxaliplatin 130 mg/m (2-h intravenous infusion); on ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Delozier T,Guastalla JP,Yovine A,Levy C,Chollet P,Mousseau M,Delva R,Coeffic D,Vannetzel JM,Zazzi ES,Brienza S,Cvitkovic E

    更新日期:2006-10-01 00:00:00

  • Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.

    abstract::Acquired docetaxel (Doc) resistance in hormone-refractory prostate cancer (HRPC) remains an ongoing clinical challenge, resulting in failed chemotherapy and tumor recurrence. However, the mechanism of Doc-resistance development in prostate cancer cells is still unclear. Here, we observed a subpopulation of prostate ca...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Qiu S,Deng L,Bao Y,Jin K,Tu X,Li J,Liao X,Liu Z,Yang L,Wei Q

    更新日期:2018-10-01 00:00:00

  • Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.

    abstract::We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer. Medical care consumption data were collected prospective...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Schmitt C,Blijham G,Jolain B,Rougier P,Van Cutsem E

    更新日期:1999-07-01 00:00:00

  • In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.

    abstract::Targeted cancer chemotherapy is a novel approach developed for the specific delivery of anticancer drugs. Tumour targeting can be achieved by combining a chemotherapeutic agent with a targeting moiety that recognizes tumour-specific or highly expressed receptors on cancer cells. We used the gonadotropin-releasing horm...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Manea M,Tóvári J,Tejeda M,Schulcz A,Kapuvári B,Vincze B,Mezo G

    更新日期:2012-01-01 00:00:00

  • Expression of inducible nitric oxide synthase (iNOS/NOS II) in the vestibule of guinea pigs after the application of cisplatin.

    abstract::It is well known that the anti-cancer drug cisplatin has an ototoxic property; however, the details are not yet evident. In this study, the expression of inducible nitric oxide synthase (INOS/NOS II) in the vestibule of guinea pigs after i.p. injections of cisplatin was examined immunohistochemically. Three days after...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Watanabe K,Hess A,Bloch W,Michel O

    更新日期:2000-01-01 00:00:00

  • Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.

    abstract::A drug-resistant cell line (EAC/Dox) was developed by repeated exposure of Ehrlich ascites carcinoma cells to Doxorubicin (Dox) in vivo in male albino Swiss mice (6-8 weeks old). The weekly i.p. injections of Dox to mice (2 or 4 mg/kg/week for 4 months) gave rise to Dox-resistant cell line EAC/Dox, which displayed typ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Choudhuri SK,Chatterjee A

    更新日期:1998-10-01 00:00:00

  • Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression.

    abstract::Dihydroartemisinin (DHA), a water-soluble active metabolite of artemisinin derivatives, is the safest and most effective antimalarial analog of artemisinin. In the present investigation, we assessed the apoptotic effect of DHA on leukemia HL60 cells and its regulation of transferrin receptor (TfR). Cell growth inhibit...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Zhou HJ,Wang Z,Li A

    更新日期:2008-03-01 00:00:00

  • MiR-29b suppresses proliferation and mobility by targeting SOX12 and DNMT3b in pancreatic cancer.

    abstract::Pancreatic cancer is one of the leading causes of solid carcinoma with the worst survival rate. The reasons for the worst survival rate include the lack of biomarkers for early detection, diagnosis at a late stage, and the limitation of the current therapy. Further study to investigate the underlying molecular mechani...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Wang L,Wang Z,Huang L,Wu C,Zhang B

    更新日期:2019-03-01 00:00:00

  • MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal.

    abstract::Lipoplatin, currently under phase III evaluation, is a novel liposomal cisplatin formulation highly effective against cancers. Lipoplatin has eliminated or reduced the systemic toxicity frequently seen for cisplatin. The objective of the present study was to determine whether the cytotoxic effect of lipoplatin is depe...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Fedier A,Poyet C,Perucchini D,Boulikas T,Fink D

    更新日期:2006-03-01 00:00:00

  • Anticancer properties of thiophene derivatives in breast cancer MCF-7 cells.

    abstract::Substitutions in thiophene structure give rise to new derivatives with different biological and pharmacological activities. The present study investigated the cytotoxicity activity of some thiophene derivatives in breast cancer cells maintained in two-dimensional (2D) or in three-dimensional (3D) culture and evaluated...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Dos Santos FA,Pereira MC,de Oliveira TB,Mendonça Junior FJB,de Lima MDCA,Pitta MGDR,Pitta IDR,de Melo Rêgo MJB,da Rocha Pitta MG

    更新日期:2018-02-01 00:00:00

  • Chemotherapy for recurrent/metastatic head and neck cancers.

    abstract::Chemotherapy is the only option of treatment for most patients presenting with a recurrent and/or metastatic head and neck squamous cell carcinoma. The triple association of cisplatin, 5-fluorouracile, and cetuximab is still the current standard for fit patients. Other schemes are currently being compared with this pr...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审


    authors: Karabajakian A,Toussaint P,Neidhardt EM,Paulus V,Saintigny P,Fayette J

    更新日期:2017-04-01 00:00:00

  • MicroRNA-301b and its target gene synaptosome-associated protein 91 as important modulators in esophageal cancer: functional experiments.

    abstract::The aim of this study was to probe the influence of microRNA-301b (miR-301b) in esophageal cancer pathogenesis. Based on the data acquired from The Cancer Genome Atlas database, we found that miR-301b was highly expressed in esophageal cancer tissues and high expression of miR-301b was related to worse prognosis in pa...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Pan F,Chen M,Song XY,Yang JD

    更新日期:2020-04-01 00:00:00

  • Novel taxanes.

    abstract::Since their addition to paclitaxel in the oncologists' armamentarium in the early 1990s, several new taxane formulations have been developed. Besides docetaxel and nab-paclitaxel, new analogs with better therapeutic profiles are being investigated. The goals of this next generation of taxanes are to improve the toxici...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审


    authors: Muggia F,Kudlowitz D

    更新日期:2014-05-01 00:00:00

  • Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.

    abstract::Overexpression of the multidrug resistance MDR1 gene product P-glycoprotein and/or the multidrug resistance-associated protein MRP confers multidrug resistance to cancer cells. The pipecolinate derivative VX-710 has previously been demonstrated to reverse MDR1-mediated multidrug resistance at concentrations of 0.5-2.5...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Germann UA,Ford PJ,Shlyakhter D,Mason VS,Harding MW

    更新日期:1997-02-01 00:00:00

  • Therapeutic effects of the angiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice.

    abstract::The therapeutic effects of the new anti-angiogenesis factor TNP-470 were examined against carcinomatous peritonitis in mice. In the first experiment using carcinomatous peritonitis caused by i.p. inoculation of 10(6) M5076 tumor cells, TNP-470 solution was injected i.p. in a bolus of 50 mg/kg body weight into two grou...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Tsujimoto H,Hagiwara A,Osaki K,Ohyama T,Sakakibara T,Sakuyama A,Ohgaki M,Imanishi T,Watanabe N,Yamazaki J

    更新日期:1995-06-01 00:00:00

  • Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells.

    abstract::Antimicrobial peptides of the cathelicidin family play a central role in the host defense system. Our group has reported previously that cathelicidin-related or cathelicidin-modified antimicrobial peptides, such as FF/CAP-18, have antiproliferative effects on the squamous cell carcinoma cell line SAS-H1 and colon canc...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Kuroda K,Fukuda T,Okumura K,Yoneyama H,Isogai H,Savage PB,Isogai E

    更新日期:2013-09-01 00:00:00

  • Para-toluenesulfonamide induces tongue squamous cell carcinoma cell death through disturbing lysosomal stability.

    abstract::Para-toluenesulfonamide (PTS) has been implicated with anticancer effects against a variety of tumors. In the present study, we investigated the inhibitory effects of PTS on tongue squamous cell carcinoma (Tca-8113) and explored the lysosomal and mitochondrial changes after PTS treatment in vitro. High-performance liq...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Liu Z,Liang C,Zhang Z,Pan J,Xia H,Zhong N,Li L

    更新日期:2015-11-01 00:00:00

  • Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.

    abstract::We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy. Treatment consisted of mitomycin C 20 mg/m2 i.v. given over 120 h (5 ...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章


    authors: Hartmann JT,Harstrick A,Daikeler T,Kollmannsberger C,Müller C,Seeber S,Kanz L,Bokemeyer C

    更新日期:1998-06-01 00:00:00

  • In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.

    abstract::ET-743 is a marine anti-cancer drug and is currently in phase I trials in which the effect of combination therapies will be investigated. Its dose-limiting toxicity in patients is hepatotoxicity. In-vitro studies have shown that ET-743 is mainly metabolized by cytochrome P450 (CYP) 3A4, but also by 2C9, 2C19, 2D6 and ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Brandon EF,Meijerman I,Klijn JS,den Arend D,Sparidans RW,Lázaro LL,Beijnen JH,Schellens JH

    更新日期:2005-10-01 00:00:00

  • Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells.

    abstract::Continuous exposure to daunorubicin (DNR) confers resistance against the drug-elicited lethality of leukemic cells and then reduces the remission rate. However, the detailed mechanisms involved in resistance development of leukemic cells to DNR remain unclear. Upregulation of aldo-keto reductases (AKRs) in human leuke...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Matsunaga T,Yamaguchi A,Morikawa Y,Kezuka C,Takazawa H,Endo S,El-Kabbani O,Tajima K,Ikari A,Hara A

    更新日期:2014-09-01 00:00:00

  • Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme.

    abstract::In our institution, 103 glioblastoma multiforme (GBM) patients aged from 55 to 83 years were treated since November 1994 as follows. All patients underwent surgical intervention (gross total resection, n = 35; subtotal resection, n = 38; stereotactic biopsy, n = 30). Subsequently all patients were offered radiotherapy...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章


    authors: Piribauer M,Fazeny-Dörner B,Rössler K,Ungersböck K,Czech T,Killer M,Dieckmann K,Birner P,Prayer D,Hainfellner J,Muhm M,Marosi C

    更新日期:2003-02-01 00:00:00

  • Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity.

    abstract::Matrix metalloproteinase (MMP)-2 and MMP-9 have been associated with the ability of tumor cells to metastasize because of their capacity to degrade type IV collagen, the main component of basement membrane, and to their elevated expression in malignant tumors. (S)-methyl 6-(benzyloxycarbonylamino)-2-(2-((S)-2,6-dioxo-...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Chen MH,Cui SX,Cheng YN,Sun LR,Li QB,Xu WF,Ward SG,Tang W,Qu XJ

    更新日期:2008-11-01 00:00:00

  • In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil.

    abstract::Since 5-fluorouracil (5-FU) was synthesized in the late 1950s it has become an important component of many anticancer treatment regimens. The increasing volume of literature accumulating about this drug is evidence that the optimal administration schedule and its combination with modulators has yet to be determined. M...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审


    authors: Findlay MP,Leach MO

    更新日期:1994-06-01 00:00:00

  • Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults.

    abstract::Cabozantinib capsules (COMETRIQ) are approved for the treatment of patients with progressive metastatic medullary thyroid cancer. Cabozantinib tablets are investigational drug products considered to be potentially preferred pharmaceutical dosing forms. Two phase I open-label single-dose studies in healthy individuals ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,随机对照试验


    authors: Nguyen L,Benrimoh N,Xie Y,Offman E,Lacy S

    更新日期:2016-08-01 00:00:00

  • Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.

    abstract::Targeted agents such as sunitinib, an oral, multitargeted receptor tyrosine kinase inhibitor, have greatly improved the prognosis for patients with metastatic renal cell carcinoma (mRCC). In this review we analyse data from sunitinib preclinical and clinical studies in detail and consider the key implications for the ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审


    authors: Ravaud A,Bello CL

    更新日期:2011-06-01 00:00:00

  • In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents.

    abstract::Protein phosphatase 2A (PP2A) is a new target for platinum (Pt)-based cancer chemotherapeutic agents. A series of novel Pt complexes containing demethylcantharidin, a modified component of a traditional Chinese medicine (TCM), [Pt(C8H8O5)(NH2R)2] 1-5 have been shown to inhibit PP2A both in its purified form and in cel...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: To KK,Ho YP,Au-Yeung SC

    更新日期:2005-09-01 00:00:00

  • Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.

    abstract::This phase I study was performed to assess the feasibility of combining cisplatin/etoposide (VP-16) with the arotinoid Ro 40-8757 and to determine the dose-limiting toxicity (DLT) of Ro 40-8757 in this combination. Patients with non-small cell lung cancer were eligible. Treatment consisted of Ro 40-8757 p.o. day 1-21,...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章


    authors: van Zuylen L,Schellens JH,Goey SH,Pronk LC,de Boer-Dennert MM,Loos WJ,Ma J,Stoter G,Verweij J

    更新日期:1999-04-01 00:00:00

  • Enhanced anticancer effect of MAP30-S3 by cyclosproin A through endosomal escape.

    abstract::Cyclosporin A (CsA) is a calcium antagonist and can enhance the efficacy of some protein drugs, but its mechanism remains unknown. In this study, MAP30, a ribosome-inactivating protein reported to have apoptotic effects on cancer cells, was fused with S3, an epidermal growth factor receptor (EGFR)-targeting peptide. I...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Song ZT,Zhang LW,Fan LQ,Kong JW,Mao JH,Zhao J,Wang FJ

    更新日期:2018-09-01 00:00:00

  • A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin.

    abstract::Glassy cell carcinoma (GCC) of the uterine cervix is a highly malignant tumor and has a poor prognosis. As yet, no effective systemic chemotherapy to this tumor has been reported. Here we describe a case of recurrent GCC that responded to paclitaxel and carboplatin combination treatment. The patient, a 32-year-old wom...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章


    authors: Hirashima Y,Kobayashi H,Nishiguchi T,Miura K,Kanayama N

    更新日期:2001-08-01 00:00:00